Evolocumab Alters Transcriptomic Signatures and Identifies Inflammatory Biomarkers in Brain-Heart Syndrome with Coronary Heart Disease History.

Overview

1. Department of Cardiology, Second Affiliated Hospital of Dalian Medical University, Dalian, Liaoning, People’s Republic of China
2. Department of Neurology, First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning, People’s Republic of China
3. Department of Gastroenterology and Hepatology, Tokyo Medical University, Tokyo, Japan
4. Institute of Heart and Vessel Diseases, Second Affiliated Hospital of Dalian Medical University, Dalian, Liaoning, People’s Republic of China

Abstract

Purpose: A history of coronary heart disease (CHD) increases the risk of Brain-Heart Syndrome (BHS) after acute stroke, partly through heightened inflammatory responses. Evolocumab, a PCSK9 inhibitor, has anti-inflammatory properties, but its transcriptomic effects in BHS patients with CHD remain unclear. This study aims to identify evolocumab-associated transcriptomic changes and inflammation-related biomarkers in this population.

Patients and Methods: Blood samples from 24 BHS patients with CHD history (12 receiving rosuvastatin alone, 12 receiving rosuvastatin plus evolocumab) underwent transcriptomic sequencing. Candidate biomarkers were identified via differential expression and machine learning, with functional enrichment and immune infiltration analyses conducted.

Results: Four candidate biomarkers were identified: WHRN (DFNB31), IL12A, and ASB14 were upregulated, while TMED7-TICAM2 was downregulated in the evolocumab combination group. These genes were enriched in pathways related to cell metabolism, signal transduction, and immune regulation. Immune infiltration analysis showed modest but detectable changes in B-cell subsets. External validation confirmed differential expression of these candidate biomarkers in CAD patients.

Conclusion: This pilot study provides preliminary insights into the molecular mechanisms of evolocumab in treating Brain-Heart Syndrome with a coronary heart disease history, identifying four inflammation-related biomarkers. These findings suggest potential targets for future investigation; however, given the exploratory nature and small sample size, further experimental and clinical validation is required before any therapeutic application.

Reproduced under the paper's license (CC BY-NC), from the paper cited above.

Code

The paper links to its data, not to its authors' code: see the Data section.

Tracing map

A tracing map links a paper to the code its authors published: this paper has none, so it has no map.

Data

Data links

• ncbi.nlm.nih.gov/geo, NCBI; found in the text, “Data Collection”

Data Sharing Statement

The datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request. The raw sequence data reported in this paper have been deposited in the Genome Sequence Archive (Genomics, Proteomics & Bioinformatics 2025) in National Genomics Data Center (Nucleic Acids Res 2025), China National Center for Bioinformation/Beijing Institute of Genomics, Chinese Academy of Sciences (GSA-Human: HRA014845) that are publicly accessible at https://ngdc.cncb.ac.cn/gsa-human. Data requests may be directed to the corresponding author Xiaofei Ji.

Reproduced under the paper's license (CC BY-NC), from the paper cited above.

Versions

The history of this record: each version stored by the harvester or made by a correction of its authors or of the maintainers of its code, and what changed in its facts. The texts of the paper (its abstract, its availability statements) are not part of it; versions that changed only those are not listed.

Version 1, 28 September 2026: the first record

Recorded: type, language, journal, volume, pages, dates, 6 authors, 4 keywords, 1 funder, 66 references.

Cite

This paper

Dong, H., Gong, X., Zhao, Z., Joyama, Y., Ji, X., & Qu, P. (2026). Evolocumab Alters Transcriptomic Signatures and Identifies Inflammatory Biomarkers in Brain-Heart Syndrome with Coronary Heart Disease History. International journal of general medicine, 19, 603395. https://doi.org/10.2147/ijgm.s603395

Similar papers

The papers with a page that share the most with this one: the tools found in their code, their categories, datasets, cited references and authors, the rarest counting most.

[1] doi:10.3389/fpsyt.2026.1828806

Integrative multi-omics and machine learning analysis identifies candidate biomarkers associated with mitochondrial quality control in major depressive disorder.

Journal: Frontiers in psychiatry

In common: genetics / omics, 4 references

[2] doi:10.1097/shk.0000000000002867

Transcriptome and Experimental Verification Identified Candidate Biomarkers Related to Mitochondrial Metabolism in Sepsis-Associated Encephalopathy.

Journal: Shock (Augusta, Ga.)

In common: genetics / omics, 4 references

[3] doi:10.1007/s12035-026-05792-1

Identification and Experimental Validation of Biomarkers Associated with PI3K/AKT Signaling Pathway in Spinal Cord Injury.

Journal: Molecular neurobiology

In common: 4 references

[4] doi:10.1038/s41598-026-54509-w

Identification and validation of palmitoylation-associated biomarkers in major depressive disorder.

Journal: Scientific reports

In common: clinical / translational, genetics / omics, 3 references

[5] doi:10.2147/ijgm.s605071

Mendelian Randomization and Single-Cell RNA Sequencing Reveal CKAP4 and PFDN5 as Tumor Cell-Specific Causal Genes for Glioblastoma.

Journal: International journal of general medicine

In common: genetics / omics, 3 references

[6] doi:10.1038/s41598-026-57238-2

Cardiac biomarkers combined with neuroimaging localization predict long-term outcomes in acute stroke patients.

Journal: Scientific reports

In common: clinical / translational, 2 references

[7] doi:10.3390/biomedicines14050998 [code]

Integrative Multi-Omics and Machine Learning Analysis Identifies Therapeutic Targets and Drug Repurposing Candidates for Alzheimer's Disease.

Journal: Biomedicines

In common: genetics / omics, 3 references

[8] doi:10.3390/jcm15176822

Predictors of Six-Month Functional Outcome After Chronic Subdural Hematoma Surgery: Logistic Regression Versus Machine Learning.

Journal: Journal of clinical medicine

In common: clinical / translational, 2 references

[9] doi:10.1038/s41591-026-04485-5 [code]

Blood-based circular RNAs for early diagnosis of Alzheimer's disease.

Journal: Nature medicine

In common: clinical / translational, genetics / omics, 2 references

[10] doi:10.3390/ijms27156925 [code]

XGBoost-SHAP Interpretable Modeling Identifies and Validates an Eight-Gene Biomarker for Hepatic Encephalopathy Risk Prediction in Cirrhosis.

Journal: International journal of molecular sciences

In common: genetics / omics, 2 references

Contribute

The authors of this paper can claim it, correct its record and validate its tracing map, and the maintainers of its code (its owner, or a public member of its organization) correct what it says of their repository; anyone signed in can ask for its removal. Every request goes to OSCR's own machine, which answers it; your account page follows them.

Request its removal

To ask OSCR to remove this record, the copies of its authors' scripts or its tracing map, use the removal request page: signed in, you say who you are, what to remove and why, then review and confirm the request. Published rules decide every request (how).

Discussion: questions and error reports about this paper and its code, from signed-in readers and its authors. It opens with sign-in.

Reproductions: reports from readers who ran the authors' code: what they reproduced, with which environment, commit and data. It opens with sign-in.

Activity: what happens around this paper: new versions of its record, its map's validation, discussions and reproductions. It opens with sign-in.